相关实验视频

Updated: Jul 24, 2025

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

对于胆道癌症的术后化疗目前的进展

Tatsuya Ioka¹, Yoshitaro Shindo², Makoto Ueno³

¹Department of Oncology Center Yamaguchi University Hospital Ube Japan.

Annals of gastroenterological surgery

|July 7, 2023

概括

术后化疗改善了胆道癌 (BTC) 的存活率. 辅助剂S-1和吉姆西塔加西斯加S-1 (GCS) 化疗对分别可切除和先进的BTC表示有前途.

科学领域:

在瘤学瘤学.
胃肠病学胃肠病学
手术瘤学手术瘤学

背景情况:

胆道癌 (BTC) 是异质的,通常在晚期被诊断出来.
彻底切除提供治愈潜力,但复发率很高,需要术后策略.
有限的随机试验存在于BTCs的术后化疗中,由于稀有性.

研究的目的:

对BTCs的辅助和新辅助化疗进行当前和正在进行的临床试验进行审查.
突出术后化疗在改善BTC患者生存结果中的作用.
讨论S-1和GCS等特定化疗方案的疗效.

主要方法:

审查最近的第三期临床试验,包括ASCOT,KHBO1401和JCOG1920.
对辅助化疗方案 (S-1) 和组合疗法 (gemcitabine,cisplatin,S-1) 的分析.
对可切除BTCs的新辅助化学疗法疗效的研究.

主要成果:

用S-1进行辅助化疗显著改善了切除BTC的整体存活率 (ASCOT试验).
杰姆西塔,加S-1 (GCS) 是高级BTC的标准,显示了改善的生存率和反应率 (KHBO1401试验).
目前正在进行的试验 (JCOG1920) 正在评估GCS作为可切除BTC的新辅助化疗.

结论:

术后化疗对于改善胆道癌症的存活率至关重要.
S-1和GCS代表了BTCs辅助和全身化疗的重大进展.
对新辅助化疗的进一步研究有望提高BTCs的治疗意图.

关键词:

的癌症的癌症胆道癌症是胆道癌症.胆瘤是一种胆瘤.胆囊癌是一种胆囊癌.在外科手术期间进行化学疗法.

更多相关视频

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

相关概念视频

Endoscopic Procedures V: ERCP

Endoscopic Procedures V: ERCP

Endoscopic Retrograde Cholangiopancreatography (ERCP) is a diagnostic procedure that combines endoscopy and fluoroscopy to diagnose and treat conditions related to the bile ducts, pancreatic ducts, and gallbladder. This procedure is beneficial for identifying and addressing blockages, gallstones, strictures, and tumors within the biliary or pancreatic systems. ERCP is both diagnostic and therapeutic, offering the ability to visualize and treat identified problems in one session.
Patient...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...